Kelly Kersten
Overview
Explore the profile of Kelly Kersten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
4604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nyberg W, Wang C, Ark J, Liu C, Clouden S, Qualls A, et al.
Immunity
. 2025 Feb;
58(2):499-512.e7.
PMID: 39909036
Genetic engineering of T cells in mouse models is essential for investigating immune mechanisms. We aimed to develop an approach to manipulate T cells in vivo using an evolved adeno-associated...
2.
Ray A, Hu K, Kersten K, Courau T, Kuhn N, Zaleta-Linares I, et al.
J Exp Med
. 2024 Nov;
222(1).
PMID: 39601781
CD206 is a common marker of a putative immunosuppressive "M2" state in tumor-associated macrophages (TAMs). We made a novel conditional CD206 (Mrc1) knock-in mouse to specifically visualize and/or deplete CD206+...
3.
Tharp K, Kersten K, Maller O, Timblin G, Stashko C, Canale F, et al.
Nat Cancer
. 2024 Jun;
5(7):1045-1062.
PMID: 38831058
Tumor progression is accompanied by fibrosis, a condition of excessive extracellular matrix accumulation, which is associated with diminished antitumor immune infiltration. Here we demonstrate that tumor-associated macrophages (TAMs) respond to...
4.
Ray A, Hu K, Kersten K, Courau T, Kuhn N, Zaleta-Linares I, et al.
bioRxiv
. 2023 Nov;
PMID: 37961697
Tumor-associated macrophages (TAMs) are frequently categorized as being 'M1' or 'M2' polarized, even as substantial data challenges this binary modeling of macrophage cell state. One molecule consistently referenced as a...
5.
Alvarez-Breckenridge C, Anderson K, Correia A, Demehri S, Dinh H, Dixon K, et al.
Cancer Immunol Res
. 2023 Oct;
11(12):1571-1577.
PMID: 37906619
The Arthur and Sandra Irving Cancer Immunology Symposium has been created as a platform for established cancer immunologists to mentor trainees and young investigators as they launch their research career...
6.
Kersten K, You R, Liang S, Tharp K, Pollack J, Weaver V, et al.
Cell Rep
. 2023 Jun;
42(6):112582.
PMID: 37261951
Pre-metastatic niche formation is a critical step during the metastatic spread of cancer. One way by which primary tumors prime host cells at future metastatic sites is through the shedding...
7.
Tanaka M, Lum L, Hu K, Ledezma-Soto C, Samad B, Superville D, et al.
bioRxiv
. 2023 May;
PMID: 37162860
Intratumoral heterogeneity (ITH)-defined as genetic and cellular diversity within a tumor-is linked to failure of immunotherapy and an inferior anti-tumor immune response. The underlying mechanism of this association is unknown....
8.
Blomberg O, Kos K, Spagnuolo L, Isaeva O, Garner H, Wellenstein M, et al.
Oncoimmunology
. 2023 Apr;
12(1):2201147.
PMID: 37089449
The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB...
9.
Blomberg O, Spagnuolo L, Garner H, Voorwerk L, Isaeva O, van Dyk E, et al.
Cancer Cell
. 2022 Dec;
41(1):106-123.e10.
PMID: 36525971
Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses...
10.
Zimmerli D, Brambillasca C, Talens F, Bhin J, Linstra R, Romanens L, et al.
Nat Commun
. 2022 Nov;
13(1):6579.
PMID: 36323660
The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer (TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but the mechanisms that lead to a therapy...